Ocular Blood Flow Imaging for Glaucoma Assessment

Not Applicable

Recruiting

• Conditions: Glaucoma
• Interventions: Device: XyCAM with oxygen

• Registration Number: NCT05726058
• Lead Sponsor: University of Maryland, Baltimore

Brief Summary

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.

The main question it aims to answer are:

* Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?

* Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring?

Participants will be

* measured for their blood pressure, heart rate, height, and weight

* dilated with tropicamide

* imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry

* imaged using the XyCAM RI while inhaling 100% oxygen through a mask

Detailed Description

The investigators will capture images of the participant's retina using the XyCAM RI or XyCAM FC ("test data") and by color fundus photography, optical coherence tomography (OCT), and standard automated perimetry (SAP) - the "standard clinical data". The investigators will perform five tests. The first two tests will be conducted using the XyCAM RI or XyCAM FC to obtain "test data". The final two tests will be conducted using routine clinical instruments to obtain "standard clinical data". The investigators will administer eye drops (Tropicamide) to dilate the participant's pupils prior to the first test. Tropicamide is a chemical that causes pupil dilation and is commonly used by doctors to examine the participant's eyes. The entire set of test data sessions should last less than eighty (80) minutes with an additional 60 minutes for carrying out the necessary procedures and imaging using the standard clinical data.

Study Timeline

• Study First Submitted: 2022-12-12
• Study First Submitted QC: 2023-02-02
• Study First Posted: 2023-02-13
• Study Start: 2023-03-30
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-09
• Last Update Posted: 2024-04-10
• Primary Completion: 2024-12-31
• Study Completion: 2025-04-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Age 18 and older with binocular vision
• Able to provide informed consent
• Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria

Read More

Exclusion Criteria

• The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)
• The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy
• The subject has prior ocular disease other than glaucoma
• The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye
• The subject has more than 15 diopters of refractive error
• The subject is a female who is pregnant or nursing
• The subject has diabetes mellitus

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pre-perimetric Glaucoma	XyCAM with oxygen	All participants with pre-perimetric glaucoma will be first be imaged pre-intervention.
Glaucoma	XyCAM with oxygen	All participants with glaucoma will be first be imaged pre-intervention.
Control	XyCAM with oxygen	All control participants will be first be imaged pre-intervention.

Primary Outcome Measures

Name	Time	Method
Blood flow velocity measure	through study completion, an average of 1 year	Dynamic video of ocular blood flow

Trial Locations

Locations (1)

University of Maryland Eye Associates at Redwood; 🇺🇸 Baltimore, Maryland, United States